Subscribe
Home
Daily Tape
Research Hub
Blog
About
Subscribe
Join 2,000+ investors
The biotech deal tape in your inbox. Free.
✓
Top news, M&A, BD&L, IPOs and VC — every morning
✓
Deal economics with investor-grade context
✓
Research Hub access: live trackers updated weekly
✓
5 minutes. Published every weekday.
Get the tape →
Latest Editions
Daily
Oct 23
Friday: $1.28B upfront for oral IL-23
Plus: Moderna's 0.58 hazard ratio meets a 21% haircut, and Treasury drafts its China biotech rules.
Oct 22
Thursday: a cure for Hep B
Roivant doubles up in uveitis, Alcon buys an eye implant, and Treasury eyes China deals.
Oct 21
Wednesday: Rapport's bipolar win lands 3.1 points, shy of its own bar
Arcus lines up casdatifan against Welireg, ICER calls most launches overpriced, and Disc banks $450M.
Oct 20
Tuesday: Merck KGaA breaks the Silence with a $1.3B bid
Roche hands Hansoh $400M upfront, Disc turns an FDA rejection into a Phase 3 sweep, and EyePoint halves headcount.
Oct 19
Monday: China walls off its platforms but keeps the $120B deal tap open
Plus Lilly's oral GLP-1 lands a two-label EU nod and Roche scores a thyroid eye first.
READ BY PROFESSIONALS AT
